According to a recent 13G filing with the US Securities and Exchange Commission, Mark Lampert‘s Biotechnology Value Fund L. P. owns 2.84 million common shares of Blueprint Medicines Corp (NASDAQ:BPMC), which amass 10.4% of the company’s outstanding stock. This is slightly more compared to 2.28 million shares Biotechnology Value Fund L. P. held in December, as reported in a previous filing.
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Blueprint Medicines Corporation is a biopharmaceutical company that focuses on helping people suffering from genomically defined diseases driven by abnormal kinase activation. Over the past 12 months, the company’s shares have dropped by 18.51%. In March, a number of analysts updated their outlook on Blueprint Medicines Corporation’s stock, including JPMorgan Chase & Co., which lowered the price target to $37.00 from $54.00, while reporting “market outperform” rating. Blueprint Medicines Corporation is scheduled to report its financial results for the last quarter on May 10 and analysts project a loss of $0.70 per share on revenue of $3.24 million.
The number of long hedge fund positions, among those followed by Insider Monkey, in this stock has dropped by 1 recently. At the end of the third quarter of 2015, there were 14 hedge funds bullish on this stock, whereas at the end of the fourth quarter of 2015 there were 13 interested investors. At the end of December, Mark Lampert’s Biotechnology Value Fund L.P. reported the biggest position, worth around $60 million, and the second most bullish fund manager was Jacob Gottlieb of Visium Asset Management with a position worth about $26.9 million. Other hedge funds that have reported long positions in this stock are Christopher Medlock James’s Partner Fund Management, Peter Kolchinsky’s RA Capital Management, and Richard Driehaus’s Driehaus Capital.
Investors who lost interest in this stock and cut off their positions are Hal Mintz’s Sabby Capital, which dumped around $6.6 million in stock, and Israel Englander’s Millennium Management, which dropped a position worth around $0.7 million.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Biotechnology Value Trading Fund OS | 0 | 170,320 | 0 | 170,320 | 170,320 | Less than 1% |
| BVF Partners OS Ltd | 0 | 170,320 | 0 | 170,320 | 170,320 | Less than 1% |
| BVF Partners | 0 | 2,840,251 | 0 | 2,840,251 | 2,840,251 | 10.4% |
| BVF Inc | 0 | 2,840,251 | 0 | 2,840,251 | 2,840,251 | 10.4% |
| Mark N. Lampert | 0 | 2,840,251 | 0 | 2,840,251 | 2,840,251 | 10.4% |
Page 1 of 11 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. 2)1
| Blueprint Medicines Corporation |
| (Name of Issuer) |
| Common Stock, $0.001 par value |
| (Title of Class of Securities) |
| 09627Y109 |
| (CUSIP Number) |
| April 29, 2016 |
| (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| o | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| o | Rule 13d-1(d) |
_______________
1 The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 2 of 11 – SEC Filing
| 1 | NAME OF REPORTING PERSON Biotechnology Value Trading Fund OS LP | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) x (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION Cayman Islands | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 0 shares | |
| 6 | SHARED VOTING POWER 170,320 | ||
| 7 | SOLE DISPOSITIVE POWER 0 shares | ||
| 8 | SHARED DISPOSITIVE POWER 170,320 | ||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 170,320 | ||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) Less than 1% | ||
| 12 | TYPE OF REPORTING PERSON PN | ||
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 3 of 11 – SEC Filing
| 1 | NAME OF REPORTING PERSON BVF Partners L.P. | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) x (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 0 shares | |
| 6 | SHARED VOTING POWER 2,840,251 | ||
| 7 | SOLE DISPOSITIVE POWER 0 shares | ||
| 8 | SHARED DISPOSITIVE POWER 2,840,251 | ||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,840,251 | ||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.4% | ||
| 12 | TYPE OF REPORTING PERSON PN, IA | ||
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 4 of 11 – SEC Filing
| 1 | NAME OF REPORTING PERSON BVF Inc. | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) x (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 0 shares | |
| 6 | SHARED VOTING POWER 2,840,251 | ||
| 7 | SOLE DISPOSITIVE POWER 0 shares | ||
| 8 | SHARED DISPOSITIVE POWER 2,840,251 | ||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,840,251 | ||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.4% | ||
| 12 | TYPE OF REPORTING PERSON CO | ||
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 5 of 11 – SEC Filing
| 1 | NAME OF REPORTING PERSON Mark N. Lampert | ||
| 2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP | (a) x (b) o | |
| 3 | SEC USE ONLY | ||
| 4 | CITIZENSHIP OR PLACE OF ORGANIZATION United States | ||
| NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 5 | SOLE VOTING POWER 0 shares | |
| 6 | SHARED VOTING POWER 2,840,251 | ||
| 7 | SOLE DISPOSITIVE POWER 0 shares | ||
| 8 | SHARED DISPOSITIVE POWER 2,840,251 | ||
| 9 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,840,251 | ||
| 10 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES | ¨ | |
| 11 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 10.4% | ||
| 12 | TYPE OF REPORTING PERSON IN | ||
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 6 of 11 – SEC Filing
| Item 1(a). | Name of Issuer: |
Blueprint Medicines Corporation, a Delaware corporation (the “Issuer”).
| Item 1(b). | Address of Issuer’s Principal Executive Offices: |
38 Sidney Street, Suite 200
Cambridge, Massachusetts 02139
| Item 2(a). | Name of Person Filing |
| Item 2(b). | Address of Principal Business Office or, if None, Residence |
| Item 2(c). | Citizenship |
Biotechnology Value Fund, L.P. (“BVF”)
1 Sansome Street, 30th Floor
San Francisco, California 94104
Citizenship: Delaware
Biotechnology Value Fund II, L.P. (“BVF2”)
1 Sansome Street, 30th Floor
San Francisco, California 94104
Citizenship: Delaware
Biotechnology Value Trading Fund OS LP (“Trading Fund OS”)
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
Citizenship: Cayman Islands
BVF Partners OS Ltd. (“Partners OS”)
PO Box 309 Ugland House
Grand Cayman, KY1-1104
Cayman Islands
Citizenship: Cayman Islands
BVF Partners L.P. (“Partners”)
1 Sansome Street, 30th Floor
San Francisco, California 94104
Citizenship: Delaware
BVF Inc.
1 Sansome Street, 30th Floor
San Francisco, California 94104
Citizenship: Delaware
Mark N. Lampert (“Mr. Lampert”)
1 Sansome Street, 30th Floor
San Francisco, California 94104
Citizenship: United States
Each of the foregoing is referred to as a “Reporting Person” and collectively as the “Reporting Persons.”
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 7 of 11 – SEC Filing
| Item 2(d). | Title of Class of Securities: |
Common Stock, $0.001 par value (the “Common Stock”)
| Item 2(e). | CUSIP Number: |
09627Y109
| Item 3. | If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: |
| | /x/ | Not applicable. |
| | (a) | / / | Broker or dealer registered under Section 15 of the Exchange Act. |
| | (b) | / / | Bank as defined in Section 3(a)(6) of the Exchange Act. |
| | (c) | / / | Insurance company as defined in Section 3(a)(19) of the Exchange Act. |
| | (d) | / / | Investment company registered under Section 8 of the Investment Company Act. |
| | (e) | / / | An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E). |
| | (f) | / / | An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F). |
| | (g) | / / | A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G). |
| | (h) | / / | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act. |
| | (i) | / / | A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act. |
| | (j) | / / | Group, in accordance with Rule 13d-1(b)(1)(ii)(J). |
| | (k) | / / | Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____ |
| Item 4. | Ownership |
| | (a) | Amount beneficially owned: |
As of the close of business on May 3, 2016 (i) BVF beneficially owned 1,342,455 shares of Common Stock, (ii) BVF2 beneficially owned 791,000 shares of Common Stock, and (iii) Trading Fund OS beneficially owned 170,320 shares of Common Stock.
Partners OS as the general partner of Trading Fund OS may be deemed to beneficially own the 170,320 shares of Common Stock beneficially owned by Trading Fund OS.
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 8 of 11 – SEC Filing
Partners, as the general partner of BVF, BVF2, the investment manager of Trading Fund OS, and the sole member of Partners OS, may be deemed to beneficially own the 2,840,251 shares of Common Stock beneficially owned in the aggregate by BVF, BVF2, Trading Fund OS, and certain Partners management accounts (the “Partners Management Accounts”), including 536,476 shares of Common Stock held in the Partners Management Accounts.
BVF Inc., as the general partner of Partners, may be deemed to beneficially own the 2,840,251 shares of Common Stock beneficially owned by Partners.
Mr. Lampert, as a director and officer of BVF Inc., may be deemed to beneficially own the 2,840,251 shares of Common Stock beneficially owned by BVF Inc.
The foregoing should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of any shares of Common Stock owned by another Reporting Person. Partners OS disclaims beneficial ownership of the shares of Common Stock beneficially owned by Trading Fund OS. Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Management Accounts, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.
| | (b) | Percent of class: |
The following percentages are based on 27,237,950 shares of Common Stock outstanding as of April 25, 2016, as disclosed in the Issuer’s Definitive Proxy Statement filed on Schedule 14A with the Securities and Exchange Commission on April 28, 2016.
As of the close of business on May 3, 2016 (i) BVF beneficially owned approximately 4.9% of the outstanding shares of Common Stock, (ii) BVF2 beneficially owned approximately 2.9% of the outstanding shares of Common Stock, (iii) Trading Fund OS beneficially owned less than 1% of the outstanding shares of Common Stock (iv) Partners OS may be deemed to beneficially own less than 1% of the outstanding shares of Common Stock, and (v) each of Partners, BVF Inc. and Mr. Lampert may be deemed to beneficially own approximately 10.4% of the outstanding shares of Common Stock (approximately 2.0% of which is held in the Partners Management Accounts).
| | (c) | Number of shares as to which such person has: |
| | (i) | Sole power to vote or to direct the vote |
See Cover Pages Items 5-9.
| | (ii) | Shared power to vote or to direct the vote |
See Cover Pages Items 5-9.
| | (iii) | Sole power to dispose or to direct the disposition of |
See Cover Pages Items 5-9.
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 9 of 11 – SEC Filing
| | (iv) | Shared power to dispose or to direct the disposition of |
See Cover Pages Items 5-9.
| Item 5. | Ownership of Five Percent or Less of a Class. |
Not Applicable.
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person. |
Partners, BVF Inc. and Mr. Lampert share voting and dispositive power over the shares of Common Stock beneficially owned by BVF, BVF2, Trading Fund OS, and the Partners Management Accounts.
| Item 7. | Identification and Classification of the Subsidiary That Acquired the Security Being Reported on by the Parent Holding Company or Control Person. |
Not Applicable.
| Item 8. | Identification and Classification of Members of the Group. |
See Exhibit 99.1 to Amendment No. 1 to the Schedule 13G filed by the Reporting Persons with the Securities and Exchange Commission on February 16, 2016.
| Item 9. | Notice of Dissolution of Group. |
Not Applicable.
| Item 10. | Certifications. |
By signing below each of the undersigned certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 10 of 11 – SEC Filing
SIGNATURE
After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
Dated: May 3, 2016
| BIOTECHNOLOGY VALUE FUND, L.P. | ||||
| BVF INC. | ||||
| By: | BVF Partners L.P., its general partner | |||
| By: | BVF Inc., its general partner | By: | /s/ Mark N. Lampert | |
| Mark N. Lampert | ||||
| By: | /s/ Mark N. Lampert | President | ||
| Mark N. Lampert | ||||
| President | ||||
| MARK N. LAMPERT | ||||
| BIOTECHNOLOGY VALUE FUND II, L.P. | ||||
| By: | BVF Partners L.P., its general partner | |||
| By: | BVF Inc., its general partner | /s/ Mark N. Lampert | ||
| By: | /s/ Mark N. Lampert | |||
| Mark N. Lampert | ||||
| President | ||||
| BVF PARTNERS L.P. | ||||
| By: | BVF Inc., its general partner | |||
| By: | /s/ Mark N. Lampert | |||
| Mark N. Lampert | ||||
| President | ||||
| BVF PARTNERS OS LTD. | |
| By: | BVF Partners L.P., its sole member |
| By: | BVF Inc., its general partner |
| | |
| By: | /s/ Mark N. Lampert |
| Mark N. Lampert | |
| President | |
| BIOTECHNOLOGY VALUE TRADING FUND OS LP | |
| By: | BVF Partners L.P., its investment manager |
| By: | BVF Inc., its general partner |
| | |
| By: | /s/ Mark N. Lampert |
| Mark N. Lampert | |
| President | |
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
Page 11 of 11 – SEC Filing
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
Follow Blueprint Medicines Corp (NASDAQ:BPMC)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
